Meropenem Qilu (Meropenem)

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

• Complicated intra‑abdominal infections: provides rapid bacterial eradication and clinical cure.
• Complicated urinary tract infections: eliminates resistant uropathogens and resolves infection.
• Skin and soft tissue infections: penetrates tissue to treat deep‑seated bacterial involvement.
• Community‑acquired and hospital‑acquired pneumonia: covers typical and atypical pathogens causing severe lung infection.
• Meningitis: achieves therapeutic concentrations in cerebrospinal fluid to treat central nervous system infections.
• Septicemia: rapidly reduces bloodstream bacterial load and improves survival outcomes.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability, cell lysis, and bacterial death. Its broad spectrum includes many Gram‑positive, Gram‑negative, and anaerobic organisms, and it resists most β‑lactamases.

Adverse reactions may occur with any intravenous antibiotic.

Common Side Effects

• Diarrhea: mild to moderate loose stools.
• Nausea: transient feeling of queasiness.
• Headache: occasional mild cranial discomfort.
• Injection site pain: local discomfort during infusion.
• Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

• Severe hypersensitivity: rash, bronchospasm, or anaphylaxis.
• Clostridioides difficile colitis: watery diarrhea with possible pseudomembranous colitis.
• Seizures: especially in patients with renal impairment or high doses.
• Renal dysfunction: rise in serum creatinine or reduced urine output.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

• Renal function: adjust dose in patients with impaired clearance.
• Allergies: avoid in individuals with known β‑lactam hypersensitivity.
• Pregnancy: use only if benefits outweigh potential risks, as safety data are limited.
• Concomitant nephrotoxins: monitor kidney function when combined with other renal‑impacting drugs.
• Therapeutic drug monitoring: consider in critically ill or renal‑compromised patients.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may alter the efficacy or toxicity of co‑administered medicines.

Major Interactions (Avoid)

• Valproic acid: risk of reduced serum levels and loss of seizure control.
• Probenecid: may increase meropenem concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: additive nephrotoxicity; monitor renal parameters.
• Loop diuretics: potential for increased ototoxicity when combined with other ototoxic agents.
• Anticoagulants: possible alteration of INR; check coagulation status regularly.